| Bioactivity | MMI-0100 is a cell-permeant peptide inhibitor of mitogen activated protein kinase activated protein kinase II (MK2). MMI-0100 reduces intimal hyperplasia ex vivo and in vivo. MMI-0100 suppresses IL-6 expression without effect on IL-8 expression. MMI-0100 suppresses fibrotic processes such as vein graft disease[1]. | ||||||
| Invitro | Naphthofluorescein (compound 19) (0-10 μM; 24 hours) suppresses the HIF-1 reporter activity in a concentration-dependent manner. [1].MMI-0100 (0.25 and 0.5 mM; 24 hours) slightly increases cell proliferation in both cell types compared to control cells treated with 20 ng/ml TNF-α alone[1].MMI-0100 (1 mM) treatment also increases both EC (11%) and SMC (7%) proliferation as compared to control, this response is not as robust as that induced by treatment with 0.5 mM MMI-0100[1].MMI-0100 does not induce EC apoptosis at any dose[1]. Cell Viability Assay[1] Cell Line: | ||||||
| Name | MMI-0100 | ||||||
| CAS | 1039342-24-9 | ||||||
| Shortening | YARAAARQARAKALARQLGVAA | ||||||
| Formula | C98H171N37O26 | ||||||
| Molar Mass | 2283.64 | ||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||
| Storage | Sealed storage, away from moisture and light, under nitrogen
*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen) |
MMI-0100
CAS: 1039342-24-9 F: C98H171N37O26 W: 2283.64
MMI-0100 is a cell-permeant peptide inhibitor of mitogen activated protein kinase activated protein kinase II (MK2). MMI
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.